3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Conditions
Pancreatic Neoplasms
2
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Pulmonary Embolism
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Fibrosis
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
685
130-nm albumin-bound paclitaxel
199
Fluorouracil
190
Oxaliplatin
177
Albumin-Bound Paclitaxel
154
Capecitabine
137
Leucovorin
133
Irinotecan
114
Radiotherapy
96
Taxes
85
pembrolizumab
81
Cisplatin
73
Erlotinib Hydrochloride
70
Radiosurgery
69
Nivolumab
56
Drug Therapy
56
Bevacizumab
54
Magnetic Resonance Spectroscopy
51
Cyclophosphamide
49
folfirinox
45
Specimen Handling
43
Docetaxel
42
Cetuximab
40
Biopsy
39
irinotecan sucrosofate
38
S 1 (combination)
36
Pancreaticoduodenectomy
35
Blood Specimen Collection
34
Surgical Procedures, Operative
31
Paclitaxel
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
apixaban
×
Gastrointestinal
×
Clear all
NCT04191928
2021-12-23
PAP-UP
Thomas Jefferson University
Phase 1
Completed
4 enrolled
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled